Loading clinical trials...
Loading clinical trials...
Clozapine or Haloperidol in First Episode Schizophrenia
This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.
This is a longitudinal double blind, 2- 5 year study of the clinical, neuroendocrine and biochemical response to clozapine (CLOZ) and haloperidol (HAL) in a group of "first episode" schizophrenic (RDC) patients. Within the protocol, we compare the differential effects of the two drugs over the short term (12 weeks) and the long-term (2-5 years); we evaluate the relationship between change in prolactin level and clinical response of the patients; and we search for biochemical predictors and correlates of clinical response. To achieve the study aims, we employ a drug-washout period, a 12-week acute treatment period; and an 88 - 260 week follow-up period.
Age
18 - 45 years
Sex
ALL
Healthy Volunteers
No
Commonwealth Research Center
Jamaica Plain, Massachusetts, United States
Start Date
March 1, 1996
Primary Completion Date
September 1, 2003
Completion Date
October 1, 2003
Last Updated
April 7, 2015
32
ACTUAL participants
Clozapine
DRUG
Haloperidol
DRUG
Lead Sponsor
Harvard Medical School (HMS and HSDM)
Collaborators
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions